Session » Immunological Complications of Medical Therapy Poster

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1988

A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

10:30AM-12:30PM: Abstract Number: 1981

Assessing Major Adverse Cardiovascular Events (MACE) Risk in Common Rheumatology Treatments

10:30AM-12:30PM: Abstract Number: 1998

Association Between Small Interfering RNA Therapy and Autoimmune Diseases: U.S. Prospective Cohort Study

10:30AM-12:30PM: Abstract Number: 1994

Clinical Patterns and Long-term Outcomes of Arthritis Triggered by Immune Checkpoint Inhibitors. A Multicenter Study

10:30AM-12:30PM: Abstract Number: 1982

Comparison of COVID-19 Infection and Mortality Rates in Vaccinated and Unvaccinated Patients with Autoimmune Inflammatory Rheumatic Disease (AIRD) Using Conventional and Biologic DMARD Therapy at an Urban Tertiary Care Hospital

10:30AM-12:30PM: Abstract Number: 2001

Complications and Treatment Use Associated with Long-term Oral Corticosteroid Therapy Among Patients with Dermatomyositis or Polymyositis

10:30AM-12:30PM: Abstract Number: 2003

Cumulative Incidence of Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis in Lung Cancer Patients with and Without Hip Osteoarthritis and Impacts on Survival

10:30AM-12:30PM: Abstract Number: 1986

Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis

10:30AM-12:30PM: Abstract Number: 1999

Effects of JAK Inhibitors on Subsets of the Innate Immune System

10:30AM-12:30PM: Abstract Number: 1980

Efficacy and Safety of Methotrexate in Immune Checkpoint Inhibitor-induced Arthritis: A Retrospective Longitudinal Monocentric Study

10:30AM-12:30PM: Abstract Number: 1997

Features of interleukin-1 and interleukin-6 Inhibitor (IL-1i/IL-6i) Related Severe Delayed Adverse Reactions in Subjects with or Without Reaction-risk Associated HLA-DRB1*15

10:30AM-12:30PM: Abstract Number: 1992

Gout FlaresFollowingImmune Checkpoint Inhibitors Treatment

10:30AM-12:30PM: Abstract Number: 1996

Granulomatous Reactions in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Literature Review

10:30AM-12:30PM: Abstract Number: 1989

Higher Early Cumulative Glucocorticoid Exposure Is Associated with Worse Progression-Free Survival in Patients with Immune Checkpoint Inhibitor Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 1990

Human Umbilical Cord Mesenchymal Stem Cell-derived Microvesicles Alleviate Pulmonary Fibrosis by Inhibiting Monocyte-macrophage Migration Through ERK1/2 Signaling-mediated Suppression of CCL2 Expression

10:30AM-12:30PM: Abstract Number: 1993

Identification of Elevated Soluble Factors in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Their Association with Severity and Persistence

10:30AM-12:30PM: Abstract Number: 1983

Immune Checkpoint Inhibitor Associated Vasculitis and Polymyalgia Rheumatica: A Systematic Review

10:30AM-12:30PM: Abstract Number: 2000

Induction of Systemic Inflammatory Diseases with Dupilumab Therapy

10:30AM-12:30PM: Abstract Number: 1991

Initial Corticosteroid Dosing and Effects on Disease Activity, Survival, and Tumor Progression in Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 2002

Pain and Physical Function, but Not Fatigue, Track with Disease Activity in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 1978.5

Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants with Rheumatoid Arthritis Treated with Nipocalimab

10:30AM-12:30PM: Abstract Number: 2004

Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center

10:30AM-12:30PM: Abstract Number: 1979

Safety and Effectiveness of Immune Checkpoint Inhibitor Therapy in Patients with Pre-existing Autoimmune Disease

10:30AM-12:30PM: Abstract Number: 1985

Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans

10:30AM-12:30PM: Abstract Number: 1995

Use of Abatacept for the Treatment of Severe Immune-related Adverse Events from Immune Checkpoint Inhibitors for Cancer: A Case Series

10:30AM-12:30PM: Abstract Number: 1984

Use of ICD Codes for the Identification of Patients with Immune Checkpoint Inhibitor Induced Inflammatory Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].